Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

NCCN Guideline Updates Expand IO/TKI Options and Precision Medicine Approaches in RCC

September 18th 2024

Moshe Ornstein, MD, MA, discusses the implications of updates to NCCN guidelines for the management of non–clear cell and clear cell renal cell carcinoma

FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 17th 2024

The FDA approved adjuvant ribociclib plus an aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.

Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC

September 17th 2024

The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.

Tislelizumab Receives Israeli Approval in Unresectable or Metastatic ESCC

September 17th 2024

Tislelizumab has been approved by the Israeli Ministry of Health for pretreated patients with unresectable or metastatic esophageal squamous cell carcinoma.

AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors

September 16th 2024

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.

TORL-1-23 Is Tolerable, Active in Heavily Pretreated CLDN6+ Advanced Ovarian Cancer, Other Solid Tumors

September 15th 2024

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Nivolumab Alone, With Ipilimumab Demonstrate Sustained 10-Year Survival Benefit in Advanced Melanoma

September 15th 2024

The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.

Ramucirumab Plus TAS-102 Fails to Improve OS in Heavily Pretreated mCRC

September 15th 2024

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

Neoadjuvant Dato-DXd Plus Durvalumab Shows Variable pCR Rates in Stage II/III Breast Cancer

September 14th 2024

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

September 14th 2024

Adjuvant pembrolizumab and chemotherapy with or without radiation showed mixed findings in patients with high-risk endometrial cancer.

DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets

September 13th 2024

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC

September 13th 2024

Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.

FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab

September 12th 2024

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC

September 12th 2024

Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.

Bria-IMT Plus Checkpoint Inhibition Maintains Favorable OS in Metastatic Breast Cancer

September 11th 2024

Updated data from a phase 1/2 study showed positive overall survival outcomes with Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer.

FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas

September 11th 2024

The FDA has granted orphan drug designation to the novel GSK-3β inhibitor elraglusib for the treatment of patients with soft tissue sarcoma.

Markman Peels Back the Curtain on the Effects of Growing Uncertainties in Gynecologic Oncology

September 11th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

TakeAim Lymphoma Tests Proof of Concept for Dual IRAK4/FLT3 Blockade in B-Cell Malignancy Treatment

September 11th 2024

Targeting IRAK4 with emavusertib could be a viable treatment option that offers needed blood-brain barrier penetration in PCNSL.

Proteomics and Prognostics May Serve as Potential Biomarkers Beyond PD-L1 in Lung Cancer

September 10th 2024

Luis Raez, MD, details several potential lung cancer biomarkers under investigation including the plasma proteomics–based PROphet test.

FDA Approval of Amivantamab Plus Lazertinib Builds Upon Success of First-Line TKIs in Advanced EGFR-Mutant NSCLC

September 10th 2024

Joshua K. Sabari, MD, discusses the significance of the FDA approval of first-line amivantamab plus lazertinib for patients with EGFR-mutant NSCLC.